The Latest
-
Stock via Getty Images
Who’s winning in biotech’s tight market?
Three of the largest fundraising rounds in 2024 show where investors are willing to place their bets in biotech.
-
Michael Vi / Getty Images via Getty Images
Q&AHow Lilly’s sustainability goals come face to face with massive growth
Eli Lilly’s head of ESG is maintaining a focus on sustainability even as the company’s expansion plans in weight loss drive a larger footprint and more social scrutiny.
-
Permission granted by Organon
Why pharma should redefine ‘women’s health’
A broader approach recognizes the challenges disproportionately impacting women and could lead to better outcomes, according to Organon.
-
Permission granted by Sanofi
3 FDA approval dates to watch in the year’s final push
A handful of potential blockbusters are marching toward FDA review.
-
George Frey/Reuters
Deep DiveA decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.
-
Getty Images via Getty Images
A new way of determining a drug’s value — with health equity in mind
Quality-adjusted life years are an important tool to frame a drug’s cost effectiveness, but they leave out other determinants of health.
-
Scott Olson via Getty Images
Lilly lays down $1B to be ‘first in biology’ with obesity gene therapies
The deal, which targets metabolic diseases, is one of a few by Big Pharma to develop lncRNA therapies.
-
Getty Images via Getty Images
Huntington’s disease R&D is regaining ground after several disappointments
Setbacks haven’t stopped advances by biotechs and pharmas working on new drugs for the inherited brain disorder.
-
Stock via Getty Images
What 3 layoff stories reveal about pharma’s troubles
The factors driving the industry’s layoffs — and what could help turn the tide.
-
Permission granted by Merck & Co.
Big Pharma is often media shy. Merck’s chief comms officer is hoping to change that.
Cristal Downing is helping Merck & Co. buck pharma’s zipped-lip status quo and usher in a “new era” of openness, transparency and “overt communication.”
-
Stock via Getty Images
Pharma’s ‘it’ therapy — a new drug class gaining steam
More companies are investing in protein degraders, which leverage a unique approach to harnessing the immune system in cancer, neurological diseases and more.
-
Permission granted by Pfizer
A plucky biotech threatening Pfizer’s grip on the Prevnar vaccine market
Results from Vaxcyte’s clinical pneumococcal vaccine study showed the smaller company could take on Pfizer’s legendary blockbuster.
-
Sarah Silbiger via Getty Images
FDA adcomm reform talks heat up
As the agency considers eliminating adcomm votes from the approval process, members vie to have their voices heard.
-
Stock via Getty Images
Is anyone taking the world’s priciest drugs?
A slew of breakthrough gene therapies won FDA approval in recent years — but high price tags haven’t always yielded big returns.
-
Getty Images via Getty Images
Their Alzheimer’s treatment worked — but shares fell anyway
Cognition Therapeutics touted what the C-suite saw as a promising mid-stage study in Alzheimer’s, but investors read a different story.
-
Stock via Getty Images
After an FDA rejection, here’s what’s next in the psychedelics pipeline
By rejecting the first MDMA therapy earlier this month, the FDA signaled to the psychedelic drug sector that the road to approval isn’t clear cut.
-
iStock via Getty Images
As pharma’s AI revolution gets underway, ‘hallucinations’ pose a great risk
While AI, machine learning and large language models can distill huge amounts of information, they sometimes make mistakes. New technologies could rebuild that trust.
-
Permission granted by Takeda Pharmaceuticals
Q&A // First 90 DaysWith a new oncology R&D head, Takeda revamps its strategy
The company is using a “three-by-four” approach to sharpen its cancer R&D aims.
-
PierreDesrosiers via Getty Images
Pharmas’ IRA court losses mount. They keep pursuing them.
The final drug prices for Medicare’s negotiation program have been published, but pharma companies continue to push their legal strategies.
-
Mario Tama/ via Getty Images
As a new mpox strain gains ground, a key drug stumbles in the clinic
Despite the disappointing results, the drug’s developer, Siga Therapeutics, said there’s more to the story.
-
Permission granted by Reed Tuckson
Lessons from COVID: Tuskegee impacts still erode trust in healthcare, but hope shines through
A long-time leader in public health and outreach to people of color, Dr. Reed Tuckson offers the lessons he learned from the COVID pandemic and how pharma can better serve those communities.
-
Courtesy of BioMarin Pharmaceutical
BioMarin taps Amgen, Roche vets in executive reshuffle
Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.
-
Getty Images via Getty Images
Will the IRA squash new drugs? Those worries are likely exaggerated, studies say.
There’s no link between revenue and R&D from smaller biotechs, and that’s where most innovation comes from, according to new studies.
-
Drew Angerer via Getty Images
Pharma’s concerns pile up months after Supreme Court’s landmark Chevron decision
The Supreme Court case added another layer of uncertainty on the regulatory front and opened up the Inflation Reduction Act to more legal attacks.
-
Courtesy of 23andMe
Q&A23andMe inches closer to cancer immunotherapy, guided by its genetic database
Dr. Jennifer Low, head of 23andMe’s therapeutics division, is taking the company into new territory with a potential cancer treatment that targets a unique pathway.
